Statin Therapy Guidelines

Benefits of Statin Therapy

The American Heart Association recommends that statins reduce the probability of cardiovascular events (myocardial infarction or ischemic stroke) and mortality by at least a moderate amount in adults with cardiovascular risk factors and elevated risk scores 1
In patients with established atherosclerotic disease, the European Society of Cardiology suggests that statins reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions 2, 3
Statins can halt progression or even contribute to regression of coronary atherosclerosis at doses that effectively reduce LDL cholesterol by 50%, according to the European Heart Journal 2
For patients undergoing vascular surgery with or without clinical risk factors, the American College of Cardiology recommends that statin use is reasonable and associated with reduced perioperative mortality 4, 5

The American College of Cardiology advises that discontinuation of statins in patients with acute coronary syndrome or those undergoing vascular interventions should be avoided as it may increase cardiovascular risk 6
For patients currently taking statins and scheduled for noncardiac surgery, the American Heart Association recommends that statins should be continued to prevent adverse cardiovascular outcomes 4
In all patients with acute coronary syndrome, the European Society of Cardiology suggests that statin treatment in high doses should be initiated as early as possible while patients are in the hospital to reduce cardiovascular events 2, 3

The American College of Cardiology recommends identifying vulnerable patients for myopathy risk, including those with advanced age (>75 years), renal impairment, or those taking interacting medications 7
The American College of Cardiology suggests monitoring liver enzymes initially, approximately 12 weeks after starting therapy, then annually or more frequently if indicated 7
The American College of Cardiology advises evaluating muscle symptoms and CK before starting therapy, then at 6-12 weeks and at follow-up visits 7
The European Society of Cardiology recommends avoiding drug interactions that may increase statin-associated adverse effects, particularly with medications that inhibit CYP3A4 2

The American Heart Association suggests that in patients >75 years of age with clinical ASCVD, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits against adverse effects when initiating or continuing statin therapy 8
The American Heart Association recommends that for patients with statin intolerance, consider alternative dosing strategies or lower-intensity statins before discontinuing therapy completely 8

High-intensity statin therapy is recommended for patients with atherosclerotic ischemic stroke or transient ischemic attack (TIA) to reduce the risk of stroke and cardiovascular events 9
Patients with a history of coronary artery disease and stroke are classified as "very high risk" for future atherosclerotic cardiovascular disease (ASCVD) events and derive significant benefit from statin therapy 9
The SPARCL trial demonstrated that high-intensity statin therapy (atorvastatin 80 mg) reduced the risk of stroke by 16% in patients with previous stroke or TIA 10

For patients ≤75 years of age with clinical ASCVD (including coronary artery disease and stroke), high-intensity statin therapy should be initiated or continued as first-line therapy, according to the American College of Cardiology 11
High-intensity statin therapy includes atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily 9
Moderate-intensity statin therapy should be used when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, as recommended by the American Heart Association 11

For patients with multiple comorbidities or on multiple medications, monitor for potential drug interactions with statins, particularly medications that inhibit CYP3A4, as advised by the European Society of Cardiology 12

The target LDL-C level for patients with established ASCVD (including stroke and coronary artery disease) should be <70 mg/dL (1.8 mmol/L), according to the American College of Cardiology 9
If LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy, it may be reasonable to add ezetimibe and then a PCSK-9 inhibitor if necessary, as recommended by the American Heart Association 9